PneumaCare launches new product to monitor lung function
The company’s latest technology provides clinicians with a non-contact and in-depth assessment of pulmonary function just hours after surgery.
“Until now, there has been nothing that has allowed such timely information to be gathered. By measuring chest wall movement in a non-contact, non-radiological way, a remarkable depth and range of information on the patient’s respiratory function is generated.” — Dr Richard Iles, PneumaCare
Cambridge Enterprise portfolio company PneumaCare has launched the Thora-3DI, which not only provides the first true bedside image of a patient’s pulmonary function, but also gives a previously unobtainable level of in-depth information. This enables the patient’s condition to be monitored easily and accurately.
“The Thora-3DI allows patients’ lung function to be assessed on recovery wards just a few short hours after leaving surgery,” says Dr Richard Iles, a consultant in respiratory paediatrics at Addenbrooke’s Hospital, Cambridge, and PneumaCare’s Chief Medical Officer. “Until now, there has been nothing that has allowed such timely information to be gathered. By measuring chest wall movement in a non-contact, non-radiological way, a remarkable depth and range of information on the patient’s respiratory function is generated. The innovative 3D and regional performance outputs provide critical lung function assessment data in a range of settings, including at the patient’s bedside, in thoracic surgery wards and in respiratory function labs.”
“What differentiates the PneumaCare technology from everything else on the market is the clever exploitation of its Structured Light Plethysmography technology to gather pulmonary benchmark and performance data for use in assessing patients,” explains Dr Ward Hills, CEO of PneumaCare. “The Thora-3DI enables clinicians to monitor the patient’s recovery and progress without having to disturb or move them. Its mobile design means that it can be set-up easily anywhere in the hospital. The release of our latest product is another example of how PneumaCare is able to determine the needs of a market segment and quickly create and produce an innovative solution to meet that need.”
While the Thora-3DI has yet to complete the 510(k) approval process in the United States it was well received when it was unveiled at the American Thoracic Society 2012 International Conference in San Francisco last week. A US commercial launch is expected later this year.
PneumaCare was founded in 2009 with funding from Cambridge Enterprise. The company was recently named a TiE50 winner, as a leader in entrepreneurship, innovation and management excellence. TiE is a global network dedicated to fostering entrepreneurs, and is sponsored by top Venture Capital Firms and Fortune 500 corporations.